Alexium International : Dr. Robert Brookins Confirmed as CEO

Perth, Australia and Greer, South Carolina- 12 July 2018- Alexium International Group Limited ('Alexium,' 'the Company') (ASX: AJX, NASDAQ Designation: AXXIY) has appointed Dr. Robert (Bob) Brookins as Chief Executive Officer and Managing Director of the Company.

In his capacity as Executive Vice President of Research and Development, Dr. Brookins has been instrumental in the research and development of the Company's innovative technologies. Dr. Brookins led the development and commercialization of Alexium's phase change material ('PCM') platform technologies and the Alexicool® product line, which is the foundation of the Company's recent success in sales to the bedding and top-of-bed markets. Dr. Brookins has, during his 8 years with the Company, been involved in multiple facets of the business, including working with customers on product design and marketing, analyzing markets to assess opportunities, and planning for logistics and supply-chain management. In addition, Dr. Brookins co-invented Alexium's flame retardant ('FR') technologies for military uniforms and formaldehyde-free, flame retardant products for cotton-based materials. Dr. Brookins has been immersed in the operations and strategy of the business and has gained significant experience working within the senior leadership team of the Company.

Dr. Brookins has demonstrated an entrepreneurial drive, a deep knowledge of Alexium's business and markets, and strong leadership to drive the vision and performance of the Company. He is committed to strategic decision making, transformative business and organizational process, and cost management.

Over the past two years, Dr. Brookins has assembled a strong Research & Development team which has been integral to the development of these technologies. Mr. Richard Estes has been a critical person in this team including as co-inventor with Dr. Brookins on the PCM and FR Alexium technologies. As part of the new organizational structure, Mr. Estes has been promoted to Vice President, Research and Development. Mr. Estes has a Bachelor of Chemistry from the University of Massachusetts at Amherst and has over 25 years of experience in materials science across a range of industries, including coatings and textiles.

Dr. Brookins stated, 'Over the past 18 months, Alexium has made great strides in the three cornerstone initiatives based on our PCM and FR platform technologies. Building on this momentum and leveraging our strengths in innovation and commercialization to progress such initiatives will be my focus, because the Company's profitability and success will be driven by these. I look forward to leading the Alexium team to accomplish this.'

Sue Thomas said, 'It has been a pleasure to work with Dr. Brookins in the last two months since I have become Chairman. In this period, Bob has demonstrated that he has the leadership qualities to deliver value to shareholders, including delivering on the three cornerstone initiatives. Importantly, two of these initiatives are currently ahead of target, and I am confident that with Bob's leadership and his team's commitment, Alexium will be able to demonstrate success in one or more of these areas in the near future.'

Summary of key terms of appointment:
Appointment:The appointment is to the position of Chief Executive Officer and Managing Director.
Term: Effective 1 July 2018, no fixed term. Notice period of three months by either party.
Total Fixed Remuneration: Dr. Brookins will be paid a fixed cash remuneration package of US$296,000 per annum, subject to annual review.
Short Term Incentive: It is anticipated that a short-term incentive package will be negotiated, and the market will be advised when this has been finalized.
Long Term Incentive: It is anticipated that a long-term incentive package will be negotiated, and the market will be advised when this has been finalized.

Click here to see the Initial Directors Interest Notice (Appendix 3X).

About Alexium International Group Limited

Alexium International Group Limited (ASX: AJX, Nasdaq Designation: AXXIY) holds proprietary patent applications for novel technologies developed to provide flame retardancy for a wide range of materials. These environmentally friendly flame retardants have applications for several industries and can be customized. Further, Alexium has developed products for a range of other applications including phase-change materials, water repellents, antimicrobials, and combinations thereof. Alexium also holds patents for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nanoparticles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and antimicrobial treatments. Applications under development include but are not limited to textiles, packaging, electronics, and building materials. Alexium's chemical treatments are currently marketed as Alexicool® and Alexiflam®. For additional information about Alexium, please visit www.alexiuminternational.com.

US Contact:

Mark Wise
Vice President, Investor Relations
[e-mail]